Last week’s phase III blowup of Eli Lilly and Co.’s solanezumab (sola) in Alzheimer’s disease (AD) struck up a familiar dirge in the failure-strewn space, and set experts to debating – again, still – the amyloid beta hypothesis, as companies that have chosen to pursue other routes continued to laud their approaches and ever-ambitious big pharma snatched up another player in the space.